Please use this identifier to cite or link to this item:
https://scholars.lib.ntu.edu.tw/handle/123456789/602263
Title:
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial